Document:

EX-4.2

 Exhibit 4.2 

 
  
 MYLAN INC., 
 as Issuer, 

SOMERSET PHARMACEUTICALS, INC., 
 as Guaranteeing Subsidiary, 
 The GUARANTORS from time to time parties hereto

 and 

THE BANK OF NEW YORK MELLON, 
 as Trustee 
  

 
 FIRST
SUPPLEMENTAL INDENTURE 
 DATED as of NOVEMBER 29, 2011 
 TO THE INDENTURE 
 DATED as of MAY 19, 2010, 

 
  

7.625% SENIOR NOTES DUE 2017 
 7.875% SENIOR NOTES DUE 2020 
  

 

 First Supplemental Indenture (this “First Supplemental Indenture”), dated
as of November 29, 2011, among Mylan Inc., a Pennsylvania corporation (the “Company”), Somerset Pharmaceuticals, Inc. (the “Guaranteeing Subsidiary”), a Delaware corporation and a Subsidiary of the Company, the
other Subsidiary Guarantors (as defined in the Indenture referred to herein) and The Bank of New York Mellon, as trustee under the Indenture referred to below (the “Trustee”). 

W I T N E S S E T H 
 WHEREAS, the Company has heretofore executed and delivered to the Trustee an indenture (the “Indenture”), dated as of May 19, 2010, providing for the issuance of 7.625% Senior Notes
due 2017 and 7.875% Senior Notes due 2020 (together, the “Notes”); 
 WHEREAS, the Indenture provides that
under certain circumstances the Guaranteeing Subsidiary shall execute and deliver to the Trustee a supplemental indenture pursuant to which the Guaranteeing Subsidiary shall unconditionally guarantee all of the Company’s Obligations under the
Notes and the Indenture on the terms and conditions set forth herein (the “Note Guarantee”); and 
 WHEREAS, pursuant
to Section 8.01 of the Indenture, the parties hereto are authorized to execute and deliver this First Supplemental Indenture. 
 NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto mutually covenant and agree for the equal
and ratable benefit of the Holders of the Notes as follows: 
 1. Capitalized Terms. Capitalized terms used herein
without definition shall have the meanings assigned to them in the Indenture. 
 2. Agreement to Guarantee. The
Guaranteeing Subsidiary hereby agrees to provide an unconditional Guarantee on the terms and subject to the conditions set forth in the Guarantee and in the Indenture including but not limited to Article 10 thereof. 

3. No Recourse Against Others. No director, officer, employee or stockholder of the Company or the Guaranteeing Subsidiary will
have any liability for any of the Company’s or the Guaranteeing Subsidiary’s obligations under the Notes, the Indenture, the Note Guarantees or for any claim based on, in respect of, or by reason of, such obligations or their creation.
Each Holder of Notes by accepting a Note waives and releases all such liability. The waiver and release are part of the consideration for issuance of the Notes and the Note Guarantee. 

4. NEW YORK LAW TO GOVERN. THE INTERNAL LAW OF THE STATE OF NEW YORK WILL GOVERN AND BE USED TO CONSTRUE THIS SUPPLEMENTAL
INDENTURE WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW TO THE EXTENT THAT THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION WOULD BE REQUIRED THEREBY. 

 5. Counterparts. The parties may sign any number of copies of this First Supplemental
Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. 
 6. Effect of
Headings. The Section headings herein are for convenience only and shall not affect the construction hereof. 
 7. The
Trustee. The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this First Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made
solely by the Guaranteeing Subsidiary and by the Company. 

  
 2 

 IN WITNESS WHEREOF, the parties hereto have caused this First Supplemental Indenture to be
duly executed and attested, all as of the date first above written. 
 Dated: November 29, 2011, 

 

			
	SOMERSET PHARMACEUTICALS, INC.
		
	By:	 	 
		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	MYLAN INC.
		
	By:	 	 
	Name:	 	John D. Sheehan
	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	DEY, INC.
		
	By:	 	 
		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	DEY PHARMA, L.P., by Dey, Inc., its general partner
		
	By:	 	 
		 	Name: Kristin Kolesar
		 	Title: Secretary

 Signature Page to May 2010 Supplemental Indenture 

 
			
	DEY LIMITED PARTNER, INC.
		
	By:	 	 
		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	EMD, INC.
		
	By:	 	 
		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	MLRE LLC
		
	By:	 	 
		 	Name: Kristin Kolesar
		 	Title: Manager
	
	MP AIR, INC.
		
	By:	 	 
		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	MYLAN BERTEK PHARMACEUTICALS INC.
		
	By:	 	 
		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	MYLAN CARIBE, INC.
		
	By:	 	 
		 	Name: Kristin Kolesar
		 	Title: Secretary

 Signature Page to May 2010 Supplemental Indenture 

 
			
	MYLAN DELAWARE INC.
		
	By:	 	 
		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	MYLAN INSTITUTIONAL INC. (formerly known as UDL Laboratories, Inc.)
		
	By:	 	 
		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	MYLAN LLC
		
	By:	 	 
		 	Name: Kristin Kolesar
		 	Title: Manager
	
	MYLAN LHC INC.
		
	By:	 	 
		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	MYLAN PHARMACEUTICALS INC.
		
	By:	 	 
		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	MYLAN TECHNOLOGIES, INC.
		
	By:	 	 
		 	Name: Kristin Kolesar
		 	Title: Secretary

 Signature Page to May 2010 Supplemental Indenture 

 
			
	 THE BANK OF NEW YORK MELLON,
 as Trustee

		
	By:	 	 
		 	Authorized Signatory

 Signature Page to May 2010 Supplemental IndentureEX-4.3

 Exhibit 4.3 

 
  
 MYLAN INC., 
 as Issuer, 

SOMERSET PHARMACEUTICALS, INC., 
 as Guaranteeing Subsidiary, 
 The GUARANTORS from time to time parties hereto

 and 

THE BANK OF NEW YORK MELLON, 
 as Trustee 
  

 
 FIRST
SUPPLEMENTAL INDENTURE 
 DATED as of NOVEMBER 29, 2011 
 TO THE INDENTURE 
 DATED as of SEPTEMBER 15, 2008, 

 
  

3.75% CASH CONVERTIBLE NOTES DUE 2015 
  

 

 FIRST SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of
November 29, 2011, among Mylan Inc., a Pennsylvania corporation (the “Company”), Somerset Pharmaceuticals, Inc. (the “Guaranteeing Subsidiary”), a Delaware corporation and a Subsidiary of the Company, the other Guarantors
(as defined in the Indenture referred to herein) and The Bank of New York Mellon, as trustee under the Indenture referred to herein (the “Trustee”). 
 W I T N E S S E T H 
 WHEREAS, the Company has heretofore executed and
delivered to the Trustee an indenture (the “Indenture”), dated as of September 15, 2008, providing for the issuance of 3.75% Cash Convertible Notes Due 2015 (the “Notes”); 

WHEREAS, the Indenture provides that under the circumstances specified therein that the Guaranteeing Subsidiary shall fully and
unconditionally guarantee the Company’s obligations under the Notes and the Indenture in accordance with the provisions set forth in Article 11 of the Indenture; and 
 WHEREAS, pursuant to the provisions of Section 10.01 of the Indenture, the parties hereto are authorized to execute and deliver this Supplemental Indenture. 

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby
acknowledged, the Guaranteeing Subsidiary, the Company and the other Guarantors and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows: 

1. CAPITALIZED TERMS. Capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture.

 2. AGREEMENT TO GUARANTEE. The Guaranteeing Subsidiary hereby provides a Guarantee in respect of the Securities on the terms
and subject to the conditions set forth in the Guarantee and in the Indenture including but not limited to Article 11 thereof. 

3. NO RECOURSE AGAINST OTHERS. No past, present or future director, officer, employee, incorporator, stockholder or agent of the
Guaranteeing Subsidiary, as such, shall have any liability for any obligations of the Company or any Guaranteeing Subsidiary under the Notes, any Guarantees, the Indenture or this Supplemental Indenture or for any claim based on, in respect of, or
by reason of, such obligations or their creation. Each Holder of the Notes or any Guarantee by accepting a Note waives and releases all such liability. The waiver and release are part of the consideration for issuance of the Notes and this
Guarantee. 
 4. NEW YORK LAW TO GOVERN. THIS SUPPLEMENTAL INDENTURE AND THE WITHIN GUARANTEE SHALL BE GOVERNED BY, AND
CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. 
 5. COUNTERPARTS. The parties may sign any number of copies
of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. 

 6. EFFECT OF HEADINGS. The Section headings herein are for convenience only and shall not
affect the construction hereof. 
 7. THE TRUSTEE. The Trustee makes no representations as to, and shall not be responsible in
any manner whatsoever for or in respect of the validity or sufficiency of, this Supplemental Indenture or for or in respect of the recitals contained herein, or the within Guarantee all of which recitals are made solely by the Guaranteeing
Subsidiary and the Company. 

  
 2 

 IN WITNESS WHEREOF, the parties hereto have caused this First Supplemental Indenture to be
duly executed, all as of the date first above written. 
 Dated: November 29, 2011, 

 

			
	 SOMERSET PHARMACEUTICALS, INC.

		
	By:	 	  

		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	DEY, INC.
		
	By:	 	  

		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	DEY PHARMA, L.P., by Dey, Inc., its general partner
		
	By:	 	  

		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	DEY LIMITED PARTNER, INC.
		
	By:	 	  

		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	EMD, INC.
		
	By:	 	  

		 	Name: Kristin Kolesar
		 	Title: Secretary

 Signature Page to September 2008 Supplemental Indenture 

 
			
	MYLAN CARIBE, INC.
		
	By:	 	  

		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	MYLAN LHC INC.
		
	By:	 	  

		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	MLRE LLC
		
	By:	 	  

		 	Name: Kristin Kolesar
		 	Title: Manager
	
	MP AIR, INC.
		
	By:	 	  

		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	MYLAN BERTEK PHARMACEUTICALS INC.
		
	By:	 	  

		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	MYLAN DELAWARE INC.
		
	By:	 	  

		 	Name: Kristin Kolesar
		 	Title: Secretary

 Signature Page to September 2008 Supplemental Indenture 

 
			
	MYLAN INSTITUTIONAL INC. (formerly known as UDL Laboratories, Inc.)
		
	By:	 	  

		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	MYLAN LLC
		
	By:	 	  

		 	Name: Kristin Kolesar
		 	Title: Manager
	
	MYLAN PHARMACEUTICALS INC.
		
	By:	 	  

		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	MYLAN TECHNOLOGIES, INC.
		
	By:	 	  

		 	Name: Kristin Kolesar
		 	Title: Secretary
	
	MYLAN INC.
		
	By:	 	  

	Name:	 	John D. Sheehan
	Title:	 	 Executive Vice President and

Chief Financial Officer

 Signature Page to September 2008 Supplemental Indenture 

 
			
	THE BANK OF NEW YORK MELLON, as Trustee
		
	By:	 	  

		 	Authorized Signatory

 Signature Page to September 2008 Supplemental Indenture

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}]]